Pancreatic Cancer Research

ResearcherHouston MethodistActive in the last 2 years

Bülent Özpolat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8602-7463; OpenAlex author ID A5040193650; NIH RePORTER profile ID 9150330. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 7)
Trials
0
Grants
1
Labs led
1
Collaborators
16
Papers, trials and grants by year

2014: 4 papers · 2015: none · 2016: 1 grant · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 9

  1. eEF2K is a poor prognostic factor and novel molecular target in pancreatic cancer: regulating tumor growth and progression via the tumor microenvironment. Last author DOI 10.1038/s41419-025-07803-w↗
  2. Delivery of Small Molecule EF2 Kinase Inhibitor for Breast and Pancreatic Cancer Cells Using Hyaluronic Acid Based Nanogels. Last author DOI 10.1007/s11095-020-2774-5↗
  3. MicroRNA-based Targeted Therapeutics in Pancreatic Cancer. First author DOI 10.21873/anticanres.13144↗
  4. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead. Last author DOI 10.21873/anticanres.13026↗
  5. Pancreatic Cancer Stem Cells and Therapeutic Approaches. Last author DOI 10.21873/anticanres.11628↗
  6. Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells. Last author DOI 10.1007/s10495-013-0927-2↗
  7. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion. Last author DOI 10.1111/jcmm.12361↗
  8. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-14-0028↗
  9. Down-regulation of 5-HT1B and 5-HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells. Last author DOI 10.1371/journal.pone.0105245↗

Grants 1

  1. Targeting Kras in Pancreatic Cancer R21CA199050↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ahmed Amine Ashour · 4 shared papers, 2014–2025 · strength 0.40
  2. Nilgün Gürbüz · 3 shared papers, 2014–2019 · strength 0.31
  3. Didem Karakaş · 1 shared paper, 2025 · strength 0.24
  4. Engı̇n Ulukaya · 1 shared paper, 2025 · strength 0.24
  5. Gabriel Lopez-Berestein · 1 shared paper, 1 shared grant, 2014–2016 · strength 0.23
  6. Anirban Maitra · 1 shared grant, 2016 · strength 0.20
  7. Ferah Cömert Önder · 1 shared paper, 2020 · strength 0.15
  8. Minela Aslan · 1 shared paper, 2018 · strength 0.12
  9. Gülinnaz Ercan · 1 shared paper, 2017 · strength 0.12
  10. Rosa F. Hwang · 1 shared paper, 2014 · strength 0.03
  11. Thiruvengadam Arumugam · 1 shared paper, 2014 · strength 0.03
  12. Bincy Philip · 1 shared paper, 2014 · strength 0.03
  13. Huamin Wang · 1 shared paper, 2014 · strength 0.03
  14. Vianey González-Villasana · 1 shared paper, 2014 · strength 0.03
  15. Zobeida Cruz‐Monserrate · 1 shared paper, 2014 · strength 0.03
  16. Craig D. Logsdon · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.